Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1958 1
1963 2
1964 2
1980 1
1981 6
1982 11
1983 18
1984 16
1985 23
1986 28
1987 62
1988 53
1989 58
1990 76
1991 67
1992 98
1993 68
1994 87
1995 83
1996 67
1997 90
1998 101
1999 133
2000 120
2001 109
2002 99
2003 123
2004 118
2005 139
2006 155
2007 153
2008 175
2009 197
2010 229
2011 213
2012 218
2013 238
2014 213
2015 227
2016 234
2017 230
2018 230
2019 222
2020 113
Text availability
Article attribute
Article type
Publication date

Search Results

4,541 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Miehlke S, Aust D, Mihaly E, Armerding P, Böhm G, Bonderup O, Fernández-Bañares F, Kupcinskas J, Munck LK, Rehbehn KU, Nacak T, Greinwald R, Münch A; BUG-1/LMC Study Group. Miehlke S, et al. Gastroenterology. 2018 Dec;155(6):1795-1804.e3. doi: 10.1053/j.gastro.2018.08.042. Epub 2018 Sep 7. Gastroenterology. 2018. PMID: 30195447 Free article. Clinical Trial.
The incidence of adverse events was 47.4% in the budesonide group, 68.4% in the mesalazine group, and 42.1% in the placebo group. ...Oral mesalazine 3 g once daily was not significantly better than placebo. ClinicalTrials.gov no: NCT01209208....
The incidence of adverse events was 47.4% in the budesonide group, 68.4% in the mesalazine group, and 42.1% in the placebo group. ... …
Systematic review: safety of mesalazine in ulcerative colitis.
Sehgal P, Colombel JF, Aboubakr A, Narula N. Sehgal P, et al. Aliment Pharmacol Ther. 2018 Jun;47(12):1597-1609. doi: 10.1111/apt.14688. Epub 2018 May 3. Aliment Pharmacol Ther. 2018. PMID: 29722441 Free article.
There does not appear to be a dose-dependent relationship of mesalazine and occurrence of adverse events. CONCLUSION: Patients on mesalazine should be monitored for worsening of ulcerative colitis and development of new onset organ dysfunction. High-dose mesalazi
There does not appear to be a dose-dependent relationship of mesalazine and occurrence of adverse events. CONCLUSION: Patients on …
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.
Kruis W, Kardalinos V, Eisenbach T, Lukas M, Vich T, Bunganic I, Pokrotnieks J, Derova J, Kondrackiene J, Safadi R, Tuculanu D, Tulassay Z, Banai J, Curtin A, Dorofeyev AE, Zakko SF, Ferreira N, Björck S, Diez Alonso MM, Mäkelä J, Talley NJ, Dilger K, Greinwald R, Mohrbacher R, Spiller R. Kruis W, et al. Aliment Pharmacol Ther. 2017 Aug;46(3):282-291. doi: 10.1111/apt.14152. Epub 2017 May 23. Aliment Pharmacol Ther. 2017. PMID: 28543263 Free PMC article. Clinical Trial.
Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks (SAG-51, n=330). ...In SAG-51, the proportion of recurrence-free patients over 48 …
Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or to receive either 1.5 g mesalaz
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Nguyen NH, et al. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742-753. doi: 10.1016/S2468-1253(18)30231-0. Epub 2018 Aug 17. Lancet Gastroenterol Hepatol. 2018. PMID: 30122356 Free PMC article.
INTERPRETATION: In patients with mildly to moderately active left-sided or extensive ulcerative colitis, combined oral and topical mesalazine therapy and high-dose mesalazine are superior to standard-dose mesalazine for induction of remission, but not mainten …
INTERPRETATION: In patients with mildly to moderately active left-sided or extensive ulcerative colitis, combined oral and topical mesala
Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials.
Picchio M, Elisei W, Tursi A. Picchio M, et al. J Gastrointestin Liver Dis. 2018 Sep;27(3):291-297. doi: 10.15403/jgld.2014.1121.273.pic. J Gastrointestin Liver Dis. 2018. PMID: 30240473 Free article.
RESULTS: Four RCTs enrolled 379 patients, 197 treated with mesalazine and 182 with placebo. Two studies provided data on symptom relief according to definition: it was achieved in 97/121 (80%) patients in the mesalazine group and in 81/129 (62.7%) patients in the pl …
RESULTS: Four RCTs enrolled 379 patients, 197 treated with mesalazine and 182 with placebo. Two studies provided data on symptom reli …
Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Hyams JS, Davis S, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo P, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis A, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Britt A, Saul B, Gotman N, Wang J, Serrano J, Kugathasan S, Walters T, Denson LA. Hyams JS, et al. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):855-868. doi: 10.1016/S2468-1253(17)30252-2. Epub 2017 Sep 20. Lancet Gastroenterol Hepatol. 2017. PMID: 28939374 Free PMC article. Clinical Trial.
Week 12 outcome data were available for 132 patients who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intravenous corticosteroids. Corticosteroid-free remission with the patient receiving mesalazine treatment only at 12 weeks was achieved b …
Week 12 outcome data were available for 132 patients who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intra …
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. D'Haens GR, et al. Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1. Aliment Pharmacol Ther. 2017. PMID: 28568974 Free article. Clinical Trial.
BACKGROUND: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC). AIM: To compare the efficacy and safety of 1600 mg and 400 mg tablet mesalazine formulations. ME …
BACKGROUND: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the t …
Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Zheng X, Zhang Z, Wang B, Li J, Qiu C, Zhang Q, Wang X. Zheng X, et al. Medicine (Baltimore). 2019 Apr;98(14):e15113. doi: 10.1097/MD.0000000000015113. Medicine (Baltimore). 2019. PMID: 30946380 Free PMC article.
Also, no obvious difference was found between OD and BD regime dosing of mesalazine regardless of total adverse events, treatment-related adverse events or serious adverse events. CONCLUSION: OD is as effective and safe as BD regime dosing of mesalazine for active U …
Also, no obvious difference was found between OD and BD regime dosing of mesalazine regardless of total adverse events, treatment-rel …
Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis.
Dias T, Santos A, Santos RM, Carvalho A. Dias T, et al. BMJ Case Rep. 2019 Feb 1;12(2):e228037. doi: 10.1136/bcr-2018-228037. BMJ Case Rep. 2019. PMID: 30709886
Mesalazine is a common treatment for inflammatory bowel disease and can be rarely associated with myopericarditis. We report a case of a 19-year-old man recently diagnosed with ulcerative colitis and started on mesalazine, who presented with chest pain 2 weeks after
Mesalazine is a common treatment for inflammatory bowel disease and can be rarely associated with myopericarditis. We report a case o
Mesalazine-related lung disease in a patient with ulcerative colitis: A case report.
Huang PH, Kuo CJ, Lin CW, Cheng YM, Hu HC, Lin CY, Su MY, Chiu CT. Huang PH, et al. Medicine (Baltimore). 2018 Nov;97(48):e13242. doi: 10.1097/MD.0000000000013242. Medicine (Baltimore). 2018. PMID: 30508908 Free PMC article.
There were few case reports of mesalazine-related organizing pneumonia so far. PATIENT CONCERNS: A 75-year-old female was diagnosed with ulcerative colitis and took mesalazine over a period of 2 years and 8 months. ...INTERVENTIONS: Under the consideration of mes
There were few case reports of mesalazine-related organizing pneumonia so far. PATIENT CONCERNS: A 75-year-old female was diagnosed w …
4,541 results
Jump to page
Feedback